Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer

OBJECTIVE: Human epidermal growth factor receptor 2 (HER2) overexpression occurs in up to 30% of breast cancer cases. Ado-trastuzumab emtansine (T-DM1) is approved to treat residual HER2-positive breast cancer after neoadjuvant therapy. The aim of this study was to determine the quality-adjusted tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Magalhães, Marcos Aurélio Fonseca, Aguiar, Pedro Nazareth, Neves, Milena Brachmans Mascarenhas, Lopes, Gilberto de Lima, del Giglio, Auro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2022
Materias:
Health Economics and Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071260/
https://www.ncbi.nlm.nih.gov/pubmed/35544899
http://dx.doi.org/10.31744/einstein_journal/2022GS6655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071260/
https://www.ncbi.nlm.nih.gov/pubmed/35544899
http://dx.doi.org/10.31744/einstein_journal/2022GS6655

Ejemplares similares